Published in Cancer Treat Rep on May 01, 1987
Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Am J Hum Genet (1998) 2.34
Second-look laparotomy in endodermal sinus tumor: a report of two patients with normal levels of alpha-fetoprotein and residual tumor at reexploration. Obstet Gynecol (1989) 1.42
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
A common gene for juvenile and adult-onset primary open-angle glaucomas confined on chromosome 1q. Am J Hum Genet (1995) 1.40
Rapid mRNA degradation mediated by the c-fos 3' AU-rich element and that mediated by the granulocyte-macrophage colony-stimulating factor 3' AU-rich element occur through similar polysome-associated mechanisms. Mol Cell Biol (1995) 1.35
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol (1985) 1.31
Molecular genetics of the glaucomas: mapping of the first five "GLC" loci. Am J Hum Genet (1997) 1.29
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem (1978) 1.26
Detection of fos protein during osteogenesis by monoclonal antibodies. Mol Cell Biol (1988) 1.15
Toxoplasmosis. Problems in diagnosis and treatment. Cancer (1983) 1.14
Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet (2001) 1.12
Homozygotes carrying an autosomal dominant TIGR mutation do not manifest glaucoma. Nat Genet (1998) 1.11
Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep (1985) 1.07
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol (1993) 1.02
Linkage results on 11Q21-22 in Eastern Quebec pedigrees densely affected by schizophrenia. Am J Med Genet (1995) 1.00
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol (1995) 1.00
Isolation of a novel iris-specific and leucine-rich repeat protein (oculoglycan) using differential selection. Invest Ophthalmol Vis Sci (2000) 0.99
GLC-3: a novel fipronil and BIDN-sensitive, but picrotoxinin-insensitive, L-glutamate-gated chloride channel subunit from Caenorhabditis elegans. Br J Pharmacol (2001) 0.98
5' untranslated sequences modulate rapid mRNA degradation mediated by 3' AU-rich element in v-/c-fos recombinants. Nucleic Acids Res (1992) 0.98
Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science (1978) 0.98
Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Am J Surg Pathol (1988) 0.97
Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol (1991) 0.95
Role of loop D of the alpha7 nicotinic acetylcholine receptor in its interaction with the insecticide imidacloprid and related neonicotinoids. Br J Pharmacol (2000) 0.95
Isolation of a ubiquitin-like (UBL5) gene from a screen identifying highly expressed and conserved iris genes. Genomics (2001) 0.95
Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer. Cancer (1988) 0.94
Directional limits on persistent gravitational waves using LIGO S5 science data. Phys Rev Lett (2011) 0.93
Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol (1989) 0.91
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol (1991) 0.90
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 0.89
Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer (1988) 0.88
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol (1989) 0.88
Prognostic factors in advanced ovarian carcinoma. J Clin Oncol (1986) 0.88
Evidence for association and linkage between atopy, airway hyper-responsiveness, and the beta subunit Glu237Gly variant of the high-affinity receptor for immunoglobulin E in the French-Canadian population. Immunogenetics (2000) 0.88
Mechanism of action of hypothalamic hormones in the adenohypophysis. Annu Rev Physiol (1979) 0.88
Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol (1982) 0.87
Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol (1988) 0.86
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol (1993) 0.85
Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol (1991) 0.84
Transcriptome of mouse uterus by serial analysis of gene expression (SAGE): comparison with skeletal muscle. Mol Reprod Dev (2004) 0.83
Stimulation of phosphatidic acid and phosphatidylinositol labeling in luteal cells by luteinizing hormone releasing hormone. Endocrinology (1983) 0.83
A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol (1985) 0.83
Cervix carcinoma: treatment with combination cisplatin and bleomycin. Gynecol Oncol (1983) 0.83
Parallel release of ACTH, beta-endorphin, alpha-MSH and beta-MSH-like immunoreactivities in rat anterior pituitary cells in culture. Mol Cell Endocrinol (1979) 0.83
Isolation, structural elucidation and synthesis of a tetradecapeptide with in vitro ACTH-releasing activity corresponding to residues 33-46 of the alpha-chain of porcine hemoglobin. Biochem Biophys Res Commun (1978) 0.83
Fibroblast growth factor stabilizes ribonucleic acid and regulates differentiated functions in a multipeptide-secreting neuroendocrine cell line. Endocrinology (1988) 0.82
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep (1986) 0.82
Mechanism of action of hypothalamic hormones in the anterior pituitary gland and specific modulation of their activity by sex steroids and thyroid hormones. Recent Prog Horm Res (1978) 0.82
Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer (1990) 0.81
LHRH rapidly stimulates phosphatidylinositol metabolism in enriched gonadotrophs. Mol Cell Endocrinol (1984) 0.81
Interferon-alpha and gamma mediated gene responses in a human breast carcinoma cell line. Breast Cancer Res Treat (1991) 0.79
A balanced 2:18 translocation and familial schizophrenia: falling short of an association. Arch Gen Psychiatry (1993) 0.79
Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer. Invest New Drugs (1988) 0.78
Germ cell malignancies of the ovary: treatment with vinblastine, actinomycin D, bleomycin and cisplatin containing chemotherapy combinations. Cancer (1982) 0.78
New aspects of the control of pituitary hormone secretion. Ann Clin Res (1978) 0.78
Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract. Cancer Treat Rep (1984) 0.78
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol (1990) 0.78
Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. J Mol Endocrinol (2004) 0.78
Vasopressin rapidly stimulates phosphatidic acid-phosphatidylinositol turnover in rat anterior pituitary cells. FEBS Lett (1985) 0.77
Induction of c-fos, calcitonin gene expression, and acidic fibroblast growth factor production in a multipeptide-secreting neuroendocrine cell line. Endocrinology (1988) 0.77
Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol (1993) 0.77
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. Ann N Y Acad Sci (1993) 0.77
Transcriptional regulation of human zeta and psi zeta globin genes. Prog Clin Biol Res (1987) 0.77
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report. J Natl Cancer Inst Monogr (1993) 0.77
Stimulation by prostaglandin F2 alpha of phosphatidic acid-phosphatidylinositol turnover in rat luteal cells. Biochem Biophys Res Commun (1983) 0.77
Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin. Breast Cancer Res Treat (1987) 0.77
Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. J Consult Clin Psychol (1990) 0.77
Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer (1983) 0.76
Phase II study of idarubicin in advanced cervical carcinoma. Am J Clin Oncol (1986) 0.76
4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Res (1989) 0.76
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer. Cancer (1995) 0.76
The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada. Int J Clin Pract (2014) 0.76
A review of second-look laparotomy for ovarian cancer. Gynecol Oncol (1986) 0.76
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs (1988) 0.76
Parallel stimulation of ACTH, beta-LPH + beta-endorphin and alpha-MSH release by alpha-adrenergic agents in rat anterior pituitary cells in culture. Mol Cell Endocrinol (1981) 0.76
Idarubicin in acute leukemia: results of US trials. Bone Marrow Transplant (1989) 0.75
The pituitary dopamine receptor. Adv Biochem Psychopharmacol (1980) 0.75
Interactions between hypothalamic and peripheral hormones in the control of prolactin secretion. Fed Proc (1980) 0.75
Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer. Cancer Treat Rep (1985) 0.75
Chemohormonal therapy and endocrine function in breast cancer patients. Cancer (1985) 0.75
Multiple factors controlling ACTH secretion at the anterior pituitary level. Ann N Y Acad Sci (1987) 0.75
Phase II trial of esorubicin in patients with advanced colorectal carcinoma. Cancer Treat Rep (1986) 0.75
Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer. Cancer Treat Rep (1987) 0.75
Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. Cancer Res (1985) 0.75
Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol (1990) 0.75
Mechanism of action of TRH: involvement of the phosphatidylinositol (PI) response in the action of TRH in rat anterior pituitary cells. Life Sci (1982) 0.75
Phase II trial of idarubicin in patients with pancreatic cancer. Cancer Treat Rep (1987) 0.75
Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer. Invest New Drugs (1989) 0.75
Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma. Cancer Treat Rep (1985) 0.75
Primary chemotherapy and the role of second-look laparotomy in non-dysgerminomatous germ cell malignancies of the ovary. Gynecol Oncol (1988) 0.75
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. Oncology (1994) 0.75
[Control of the parallel release of ACTH, beta-endorphin + beta-LPH and their fragments in cultured adenohypophyseal rat cells]. Union Med Can (1981) 0.75
Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy. Gynecol Oncol (1991) 0.75
Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol (1993) 0.75
[Specific role of sex steroids on the pituitary level. Sex steroids and anterior pituitary secretion]. Bull Schweiz Akad Med Wiss (1978) 0.75